Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors (PERMED01)

Institut Paoli-Calmettes

Status: Unknown

Conditions: Neoplasm Metastasis

Treatments: Other: blood sampling; Procedure: biopsy or surgical sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT02342158

PERMED01-IPC 2014-003

Details and patient eligibility

About

PERMED01 is a prospective monocenter clinical trial which aims to evaluate the number patients with locally advanced or metastatic cancer for whom identification of molecular alterations in tumor samples can lead to the delivery of a targeted therapy. PERMED01 will enroll 460 patients in 3 years.

Enrollment: 550 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age>18 years
• Histological diagnosis of cancer
• Locally advanced or metastatic, biopsiable disease
• ECOG Performans Status ≤2
• Affiliation to social security
• Signed informed consent.

Exclusion criteria

• Emergency, Individually deprived of liberty or placed under the authority of a tutor
• Patients with symptomatic or progressive brain metastasis
• Patients who have only bone and/or brain metastases
• Pregnant or breastfeeding women

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

550 participants in 1 patient group

Locally advanced /metastatic cancer

Experimental group

Treatment:

Procedure: biopsy or surgical sampling

Other: blood sampling